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Abstract
Lithium is widely used to treat bipolar disorder, but its primary mechanism of action is uncertain. One proposal has
been that lithium’s ability to inhibit the enzyme inositol monophosphatase (IMPase) reduces the supply of recycled
inositol used for membrane phosphoinositide (PIns) synthesis. This 28-year-old hypothesis is still widely debated,
however, largely because total levels of PIns in brain or in cultured neurons do not decrease after lithium treatment.
Here we use mature cultured cortical neurons to show that, although lithium has little effect on steady-state levels of
either inositol or PIns, it markedly inhibits the rate of PIns synthesis. Moreover, we show that rapid synthesis of
membrane PIns preferentially uses inositol newly imported from the extracellular space. Unexpectedly, we also ﬁnd
that the antidepressant drug ﬂuoxetine (FLUO: Prozac) stimulates the rate of PIns synthesis. The convergence of both
lithium and FLUO in regulating the rate of synthesis of PIns in opposite ways highlights PIns turnover in neurons as a
potential new drug target, as well as for understanding mood control in BD. Our results also indicate new avenues for
investigation of how neurons regulate their supply of inositol.
Introduction
Bipolar disorder (BD) is a prevalent, costly and life-
threatening illness, characterized by mood swings from
depression to mania/hypomania, interspersed with peri-
ods of normal mood1. Lithium has been the major mood-
stabilizing treatment for the disorder for 50 years. More
recently, drugs developed for other illnesses have proved
useful as mood stabilizers, including the anticonvulsants
valproate (VPA) and lamotrigine (LTG), and various
antipsychotics2. Antidepressant drugs are often used to
treat depressive episodes, but they are usually given
together with a mood stabilizer because they can desta-
bilize the illness or precipitate a manic episode3. All the
mood-stabilizing drugs have side effects that discourage
bipolar individuals from taking them, so there is an urgent
need to develop more speciﬁc drugs. In order to develop
better drugs, there is ﬁrst the need to understand the
molecular basis of the illness. One-way forward is to
analyse the relevant signalling pathways involved in
lithium’s therapeutic action and to investigate why con-
ventional antidepressant drugs destabilize mood in bipo-
lar individuals but not in those with unipolar depression.
There are two major candidate target proteins for
lithium’s primary therapeutic action – inositol mono-
phosphatase (IMPase), encoded by the gene IMPA-14,
which mRNA is enriched in neuronal axons5, and glyco-
gen synthase kinase-3 (GSK-3)6. Both are inhibited at
concentrations of lithium that approximate its therapeutic
blood levels of 0.4–1mEq/L, whereas the Ki for lithium’s
inhibition of IMPase-2 is much higher than for IMPase-1
(10 mM vs 0.8 mM)7,8. Berridge, Downes and Hanley
(1989)9 proposed that lithium’s ability to control BD
depends on the inhibition of IMPase, which they
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suggested would decrease the supply of recycled inositol
used for phosphoinositide (PIns) synthesis. This ‘inositol
depletion’ hypothesis was attractive because it took
account of the unusual uncompetitive kinetics of lithium’s
inhibition of IMPase: inhibition is only seen when
IMPase’s substrate, IP1, accumulates (see Fig. 1 for the
PIns cycle and abbreviations). This suggested a mechan-
ism in which lithium inhibition would be conﬁned to
neurons with high rates of PIns turnover, thus providing
an explanation for the relative brain speciﬁcity of its
action.
In support of this hypothesis, lithium has previously
been shown to decrease steady-state levels of PIns in
neurons: these effects, however, were only seen when PIP2
hydrolysis was hyper-stimulated for a prolonged period
with the cholinergic agonist carbachol10,11, and this
extreme pharmacological manipulation is unlikely to be
relevant to normal brain function. Other studies that
argue against a therapeutic role for IMPase inhibition
have focussed on lithium’s effects on brain inositol and/or
PIns levels. Lithium treatment transiently lowers brain
levels of inositol (which are estimated to be ~6mM) by
~25%, but it does not change brain PI or PIP2 levels
12,13.
Whole brain biochemical studies14 or inositol imaging of
the brain15,16, however, gives no indication of how lithium
might affect inositol and PIns metabolism in the sub-
populations of neurons involved in mood control. Beha-
vioural analysis of mice with targeted gene disruption of
either inositol transporters or of IMPase are consistent
with a lithium effect on the PIns cycle17–19, although the
molecular basis of lithium’s action remains unclear. Given
the controversy regarding lithium’s effects on ‘inositol
depletion', the focus for lithium’s therapeutic action
shifted to inhibition of GSK-38,20,21.
Our previous work22,23 showed that lithium and antic-
onvulsant mood-stabilizing drugs have common inositol-
reversible effects on neuron growth cone morphology.
This ﬁnding re-kindled interest in inhibition of IMPase as
a relevant therapeutic target for lithium, although a bio-
chemical demonstration of an effect on PIns synthesis was
missing. These ﬁndings led us to investigate both lithium’s
and the antidepressant ﬂuoxetine’s (FLUO: Prozac) action
on PIns metabolism using neurons from rat cerebral
frontal cortex, a brain region known to be involved in
mood control.
These cultured cortical neurons do not express
mRNA encoding the inositol synthesizing enzyme myo-
inositol phosphate synthase (MIP-synthase)22, and so
the neurons are dependent on the supply of inositol
from the extracellular ﬂuid. This arrangement is similar
to that in vivo where MIP-synthase protein is conﬁned
to endothelial cells of the brain vasculature24. The
cortical neurons also do not express mRNA encoding
either of the two high capacity sodium-dependent myo-
inositol transporters (SMITs-1 and 2), but they do
express mRNA encoding the H+-dependent myo-ino-
sitol transporter (HMIT)22,25. In the brain, SMIT-1
mRNA is expressed mainly in astrocytes and the chor-
oid plexus (but also by some neurons)26,27 (SMIT-2
mRNA is only in the meninges). The majority of neu-
rons in the neocortex do express HMIT mRNA and
protein, but Di Daniel et al.28 reported that cultured
cortical neurons from mice with a null deletion of the
HMIT gene import inositol from the extracellular space
in a similar fashion to wild-type neurons. It is therefore
unclear how these neurons take up inositol, which is a
major hole in our current understanding of PIns
metabolism in neurons.
It seems likely that the high concentrations of inositol in
brain are located mainly in the non-neural cells expres-
sing SMIT-1, SMIT-2 and MIP-synthase. Most previous
studies of lithium’s effects in PIns synthesis used either
cell lines that expressed the high capacity SMITs29 or
cerebellum granule cell neurons in which the status of
SMIT-1 was not documented10,11; these cells have mM
levels of intracellular inositol30,31, which has contributed
to the scepticism about inhibition of IMPase leading to
inositol depletion as relevant to lithium’s therapeutic
effects. Thus, a reinvestigation of the effect of lithium on
inositol and PIns metabolism in primary neurons lacking
SMITs is needed.
In this article, we show that large changes in extra-
cellular and intracellular inositol levels have no effect on
steady-state levels of PIns in cultured cortical neurons.
Moreover, the majority of the inositol used for rapid
synthesis of PIns is acquired from the extracellular
space. We show that lithium has little or no effect on
steady-state levels of either cytosolic inositol or
Fig. 1 Schematic of the phosphoinositide (PIns) cycle. The key
enzymes referred to in the article are indicated: (1) Inositol
monophosphatase (IMPase), which is inhibited by lithium ions, and (2)
Phosphatidylinositide synthase (PI-synthase) and the reverse
phosphatidylinositol: inositol exchange reaction. The double arrows
indicate the inﬂux and efﬂux of inositol across the plasma membrane.
Other abbreviations are: CDP-DAG cytidine diphosphate
diacylglycerol, PI phosphatidylinositide, PIP phosphatidylinositide
phosphate, PIP2 phosphatidylinositide-4,5-bisphosphate (this is the
most abundant of the PIP2 species), DAG diacylglycerol, PA
phosphatidic acid, IPs inositol phosphates with various numbers of
attached phosphate groups, as indicated by the subscripts
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membrane PIns. In contrast, lithium markedly inhibits
the rate of PIns synthesis: we propose that this inhibi-
tion is due, in part at least, to the accumulation of IP1.
We also show that FLUO markedly decreases cytosolic
inositol levels without affecting steady-state PIns levels,
but that FLUO increases the use of recycled inositol for
PIns synthesis.
Materials and methods
Cell culture
The cerebral cortices were dissected from E17 Sprague-
Dawley rats, collected in Ca++-free–phosphate-buffered
saline, and dissociated mechanically to single cells. Cells
were plated in 6- or 12-well plates (Nunc) (pre-coated
with poly-D-lysine) at ~1–2 × 106 cells per well and grown
in Neurobasal medium supplemented with B27, Gluta-
MAX-1, penicillin/streptomycin and nerve growth factor
(7S form NGF: 50 ng/ml) (all from Invitrogen) at 37 °C
and with 6% CO2. Cytosine arabinoside (ara-C) was added
at 5 × 10−6 M between days 1 and 5 to eliminate non-
neural cells; the addition of NGF allowed us to completely
replace the growth media after ara-C treatment and to
replace 50% 1 day prior to the experiment on day 11
(D11). Cultures were checked by microscopy before use to
ensure that there were no visible ﬂat cells; the ﬂat cells
seen in D11 cultures without ara-C were identiﬁed as
astrocytes by immunohistochemistry.
Inositol labelling
PIns and inositol in neurons were labelled to steady
state between days 6 and 11 (D6–11) with 5–10 μCi/ml of
3H-myo-inositol added to the media (speciﬁc activity
30 Ci/mmol: American Radiochemicals Inc.). (Note: we
refer to myo-inositol as simply inositol elsewhere in this
article.) For rapid synthesis and inﬂux experiments, 3H-
inositol was added for 1 h. For efﬂux experiments, neu-
rons were labelled for 5 days (D6–11), then washed
rapidly; these neurons were re-fed with growth medium,
with or without drugs, and returned to the CO2 incubator
at 37 °C (for 1 h or as stated) before collecting the media
for counting (efﬂux) and then extracting the cytosol and
membranes sequentially.
Washing
Radioactivity was removed from the extracellular space
by washing (3 × 2–3ml) with a salt solution based on the
salt composition of Neurobasal medium32, except that the
NaHCO3/CO2 buffer was replaced by 10mM HEPES:
5 mM NaOH (pH 7.4 in air) and the osmolarity due to the
B27 additive was compensated for with additional NaCl;
total osmolarity of the wash solution was 270 mOs cf.
Neurobasal medium 274mOs. The wash solution was
warmed to 37 °C before use.
Extractions
Acid soluble and membrane PIns were extracted and
analysed by strong anion-exchange high-pressure liquid
chromatography (SAX-HPLC) using a modiﬁcation of the
methods described by Azevedo and Saiardi33 and Dove
and Mitchell34 and in Supplemental Methods. Brieﬂy, 2M
perchloric acid was used to extract components in the
cytosol: these extracts would also contain acid-soluble
components from intracellular compartments and com-
ponents attached to membranes, but for convenience we
refer to all the acid-soluble components as cytosol in the
text and in the ﬁgures. The cell membranes were then
scraped off with an acidic/methanol solution and the
lipids extracted with chloroform: two phases were gen-
erated, the chloroform layer containing the lipid PIns and
the polar layer, which had minimal radioactivity; there
was also a white interphase layer of unknown composi-
tion. In 5-day labelling experiments, the interphase layer
contained ~10% of the radioactivity found in the lipid
extracts and this was not affected by drug treatments. In
1-h labelling experiments, the radioactivity in the inter-
phase layer was negligible.
For the ﬂux experiments, cytosolic components were
extracted in 2M perchloric acid (2 × 200 μl/well for a 12-
well plate) and the lipid membranes were then scraped off
in 0.1M NaOH/0.1% Triton-X100 (2 × 200 μl/well) and
the lipid extracts allowed to dissolve in capped scintilla-
tion tubes over 2 days at 20 °C before the addition of 5 ml
of scintillation ﬂuid (Ultima-Flo AP LCS-mixture; Pack-
ard). The counting efﬁciency of a constant amount of
radioactivity was within ± 10% in the acid or basic extracts
and in the Neurobasal medium. In 5-day labelling ﬂux
experiments, the radioactivity in the NaOH extracts were
not corrected for the presence of the non-lipid compo-
nents (~10% total cpm). Radioactivity was expressed
routinely as counts per minute per well (cpm/well).
Statistical analyses
Data were analysed where appropriate by one-way
analysis of variance followed by unpaired t-test. Data from
individual experiments are presented in the ﬁgures as
either means ± the standard deviation (SD) or ± the stan-
dard error of the mean (SEM) as indicated, where the 'n'
refers to the number of wells used for each condition;
each composite shows data from neurons plated at the
same time except for Fig. 4 where a and b were from a
separate plating to those used for c and d. The average
changes calculated from similar experiments using neu-
rons from separate platings are presented in the text as
mean ± SEM and the number of separate experiments
indicated. Statistically signiﬁcant differences from con-
trols are indicated on the ﬁgures by *(p < 0.05), **(p < 0.01)
or ***(p < 0.005).
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Results
Rat cortical neurons were plated and grown at a con-
stant number per well and cultured in deﬁned medium for
10–12 days. At this point, the axon outgrowth was stable,
there were many synaptic proﬁles seen by electron
microscopy (Supplemental Figure S1), and there were no
visible non-neural cells. These cultures have been shown
to contain glutaminergic and GABAergic neurons and to
be electrically active after ~ day 8. Inositol uptake was not
inhibited by phloridzin in the dose range 30–600 μM,
which is known to inhibit both SMITs-1 and -231,35. We
added 3H-inositol to the growth medium, which was
taken up by the neurons and incorporated into their
membranes. Because the neurons do not synthesize ino-
sitol, the levels of radioactivity in cytosolic 3H-inositol,
3H-IPs and membrane 3H-PIns (expressed as cpm/well)
reﬂect the relative total amounts of each of these
components.
Extracellular inositol does not inﬂuence the levels of PIns
We ﬁrst investigated how extracellular inositol levels
affect the steady-state levels of cytosolic and membrane
inositides by culturing neurons for 5 days in medium
containing 3H-inositol and one of three concentrations of
inositol: 40 μM (inositol concentration in Neurobasal
medium and approximate blood level) or 300 μM or
1000 μM [estimated cerebral spinal ﬂuid (CSF) levels are
~130 μM36,37]. After washing, we extracted the neurons
sequentially with acid (for cytosolic components) followed
by methanol/chloroform (for membranes), and analysed
the relative amounts of 3H-labelled components in each
extract using SAX-HPLC (see Supplemental Figure S2).
The 7.5- and 25-fold changes in extracellular inositol
caused only 1.9- and 4.5-fold changes, respectively, in
intracellular levels of 3H-inositol, with smaller changes in
the levels of individual cytosolic IPs(1–4) (no changes
occurred in the levels of IPs(5, 6)) (Figs. 2a, b). In contrast,
Fig. 2 Relative steady-state levels of inositol, IPs and lipid PIns in cortical neurons cultured in various levels of inositol. Neurons were grown
for 5 days (D6–11) in various concentrations of inositol as shown, together with 3H-inositol (10 µCi/ml). Histograms show the cpm/well in fractions
from SAX-HPLC analysis (see also Figure S2). Data were normalized for constant speciﬁc activity of 3H-inositol by dividing the cpm by 7.5 (for 40 μM
inositol) and multiplying the cpm by 3.3 (for 1000 μM inositol). Therefore, the Y axis (adjusted cpm/well) indicate the cpm corrected for speciﬁc
activity. Data shown are the mean and range from duplicate samples; the experiment was repeated with similar results. a Relative levels of cytosolic
inositol and b relative levels of IPs(1–4). c Same data as in (a, b) but shown on a log10 scale. The ratios of each component at the different
concentrations of inositol are indicated by the lines. d, e Relative levels of membrane PIns extracted from the same neurons used to generate data in
(a), (b) and (c) shown on a linear (d) and a log10 scale (e). The ratios of each component at the different concentrations of inositol are indicated by the
lines as shown
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there were no changes in the levels of membrane PIns
(3H-PI, 3H-PIP or 3H- PIP2) in response to the 4.5-fold
change in intracellular inositol and the 25-fold change in
extracellular inositol (Figs. 2d, e). These results indicate
that neither the extracellular nor the intracellular con-
centration of inositol is the major regulator of steady-state
levels of PIns in cortical neurons.
Note that, in this experiment and others after steady-
state labelling for 5 days, the ratio of 3H-inositol incor-
porated into membranes to the amount in the cytosol
(using media with 40 μM inositol) was on average 4.9 ± 0.7
(n= 5 experiments). When hydrolysis of PIP2 was sti-
mulated with either carbachol or by membrane depolar-
ization with 40mM KCl to produce IP3, the majority of
this IP3 was rapidly converted to IP2, IP1 and inositol
within 30 s (Supplemental Figure S3a): this recycling of
inositol from PIns is referred to as ‘the PIns cycle’ and is
indicated by the bold arrows in the diagram (Fig. 1). After
20 min of stimulation, all of the IP3 was converted to IP2,
IP1 and inositol with a small fraction converted to IP4
(Supplemental Figure S3b). In 5-day steady-state 3H-
inositol labelling experiments, electrical activity in the
neurons drives PIns hydrolysis with the majority of IP3
dephosphorylated but a small fraction of IP3 phosphory-
lated to generate labelled IPs(4–6).
Lithium and FLUO effects on steady-state levels of inositol
and PIns
We analysed the steady-state levels of inositol, IPs and
PIns after treating the neurons with either 1 mM lithium
or 3 μM FLUO for 20 h. As shown in Figs. 3a, b, lithium
had no signiﬁcant effect on the level of inositol, but it
induced a small decrease in PIP. Lithium, however, caused
a marked accumulation of IP1, the substrate for IMPase,
such that its level was 1.6-fold greater than that of inositol
(Fig. 2a). Lithium also inhibits inositol polyphosphate-1-
phosphatase (IPPase) with uncompetitive kinetics (Ki
0.3 mM)8,38, but the increase in the level of its substrate,
IP2, was small (Fig. 3a); there was no accumulation of IP3
or of IP(4–6) as suggested by Sade et al
39. In three separate
experiments, the increase in the level of IP1 after lithium
treatment was 8 ± 0.8-fold compared with a 1.7 ± 0.07-
fold increase in IP2.
FLUO consistently decreased the levels of intracellular
inositol to a much greater extent than lithium (by 45% in
Fig. 3a), but it had no effect on the steady-state levels of
PI, PIP or PIP2 (Fig. 3b); other examples of FLUO effects
are shown in Figs. 4c, d and Supplemental Figure S5.
These results with FLUO argue strongly against the
notion that lithium inhibits PIns synthesis because of
‘inositol depletion’ in these neurons, as originally sug-
gested by Berridge et al.9; they are also consistent with our
ﬁnding that intracellular inositol levels do not determine
the steady-state levels of PIns in these neurons.
PIns metabolism in neurons
We next looked at the effects of lithium and FLUO on
the rate of synthesis and degradation of PIns as it was
effects on turnover of PIns rather than their steady-state
levels that ﬁrst attracted the attention of Hokin and
Hokin and led to the discovery of the PIns signalling
system40. We exposed the neurons to 3H-inositol for
short periods (10 min, 1 h and 3 h) before extracting and
analysing the incorporation of 3H-inositol into lipid PIns
and degradation products in the cytosol. We found that
both uptake of inositol and its incorporation into mem-
branes increased from 10 min over 3 h: 3H-IP1,2 were
detected in the cytosol after 10 min, 3H-IP3,4, after 1 h,
whereas 3H-IP5 was detected after 3 h (Supplemental
Figure S4). We decided to use a 1-h exposure to assess
the rate of inositol uptake and synthesis of PIns after drug
treatment.
Lithium inhibits the rate of PIns synthesis
We tested the two drugs on the rate of PIns synthesis
using neurons from the same plating as those used for
steady-state labelling in Figs. 3a, b. As shown in Figs. 3c,
d, ~50% of the 3H-inositol taken up into the neurons in
1 h was incorporated into membranes, and radioactivity
was also found in cytosolic IP1 and IP2 (Figs. 3c, d). In
contrast to measuring steady-state levels (5 days label-
ling), lithium very signiﬁcantly (p < 0.01) decreased the
incorporation of 3H-inositol into both PI and PIP by
34% (assessed relative to control), although incorpora-
tion into PIP2 was not affected (Fig. 3d): there was a 19%
decrease in the level of 3H-inositol and an equivalent
increase in the level of 3H-IP1 such that total cytosolic
radioactivity was unaffected by lithium (Fig. 3c). Similar
results were obtained in four separate experiments, and
the average inhibition of the rate of incorporation of
inositol into membrane PIns by lithium was 46 ± 4 %
(see also Fig. 4a).
FLUO decreased the level of 3H-inositol in the cytosol
after 1 h by 46% (Fig. 3c), which is equivalent to the
FLUO-induced decrease in steady-state levels of inositol
in neurons from the same plating (Fig. 3a). In contrast to
the lack of effect on steady-state levels of PIns, FLUO
inhibited the rate of incorporation of 3H-inositol into PI,
PIP and PIP2 compared with controls; each of these
highly signiﬁcant (p < 0.005) decreases indicated by the
symbol (ϕ) was directly proportional to the decrease in
the steady-state level of inositol (the average decrease in
the ﬁve components in Figs. 3a, c, d was 45 ± 2%). These
results with FLUO are in contrast to the effect of
lithium, where the decreases in the rate of incorporation
of 3H-inositol into PI and PIP (each 34%) occurred
without a change in total cytosolic inositol plus IP1 and
with no change in the steady-state level of cytosolic
inositol.
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Inositol rapidly crosses the plasma membrane
We then looked in more detail at the ﬂux (in and out) of
3H-inositol across the plasma membrane. For inﬂux, we
labelled for 1 h and then washed the neurons and
extracted the cytosol and membranes sequentially. For
efﬂux, we labelled to steady state for 5 days with the same
speciﬁc activity of 3H-inositol, using neurons from the
same plating as those used for inﬂux; we washed the
neurons, and after 1 h collected the medium (efﬂux),
before extracting the cytosol and membranes sequentially.
We quantitated the radioactivity without separating
components by chromatography. As shown for lithium in
(Figs. 4a, b) and FLUO in (Figs. 4c, d), the majority of 3H-
inositol inﬂux in control neurons was incorporated into
membranes in 1 h (66 and 74 % respectively, ﬁrst bars in
Figs. 4a, c). Strikingly, the efﬂux of 3H-inositol in 1 h
(white bars) from control neurons was perfectly matched
to the total inﬂux (cytosol plus lipid) of untreated con-
trols. As shown in the controls in Figs. 4b, d (steady-state
labelling for 5 days), the efﬂux was ~50 % of the total
soluble pool of 3H-inositol and 3H-IPs (light grey bars). In
other similar experiments, the average proportion of
inﬂux incorporated into lipid in 1 h was 69 ± 1.5% (n= 5)
and the average efﬂux compared with the cytosolic
steady-state labelling radioactivity was 50 ± 2.6% (n= 4).
The rapid exchange of cytosolic inositol with extracellular
Fig. 3 Effect of lithium and FLUO on steady-state levels of PIns and the rate of PIns synthesis. a Neurons were labelled to steady-state for
5 days (D6–11) with 3H-inositol (10 µCi/ml) in presence of 300 μM inositol and treated for 20 h with 1 mM lithium or 3 μM FLUO as indicated prior to
acid extraction of the cytosol. Histograms show the cpm/well in fractions from SAX-HPLC analysis. Data are the mean and range from duplicate
samples. The symbol *** indicate a highly signiﬁcant (p < 0.005) increase in IP1 after lithium treatment compared with controls and the symbol (ϕ)
indicates a highly signiﬁcant (p < 0.005) decrease in inositol levels after FLUO compared with controls. Data shown are the mean ± SD, n= 3. b Lipids
were extracted from the same neurons used for (a) and processed for chromatography of the glycerophosphoinositide head groups. Histograms
show the cpm/well in fractions from SAX-HPLC analysis. Data are the mean and range from duplicate samples. The symbol * indicates a signiﬁcant
(p < 0.05) decrease in PIP due to lithium; similar data were obtained in three separate experiments. c Neurons from the same plating as those used to
generate data in (a, b) were labelled for 1 h with 3H-inositol prior to acid extraction of the cytosol. Neurons were also treated for 20 h prior to
extraction with 1 mM lithium or 3 μM FLUO as indicated. Histograms show the cpm/well in fractions from SAX-HPLC analysis. Data shown are the
mean ± SD, n= 3. The symbols * and *** indicate a signiﬁcant (p < 0.05) or highly signiﬁcant difference (p < 0.005), respectively, with lithium
treatment compared with controls. The symbol (ϕ) indicates a highly signiﬁcant (p < 0.005) decrease in inositol levels of 45% with FLUO treatment
compared with controls. d Lipids were extracted from the same neurons used for (c) and processed for chromatography of the
glycerophosphoinositide head groups. Histograms show the cpm/well in fractions from SAX-HPLC analysis. Data shown are the mean ± SD, n= 3.
The symbols ** indicate very signiﬁcant differences (p < 0.01) with lithium treatment compared with controls. Similar data were obtained in three
separate experiments. The symbols (ϕ) indicates a highly signiﬁcant (p < 0.005) decrease in levels of PI, PIP and PIP2 with FLUO treatment compared
with controls; these decreases were all equivalent to the ~45% decrease in inositol shown in (c)
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inositol, together with the high proportion of newly
acquired inositol that is incorporated into membrane,
indicates that rapid PIns synthesis depends primarily on
inositol newly imported from the extracellular space.
These data also suggest that the pool of cytosolic inositol
in regions of rapid PIns turnover may be negligible.
In order to increase turnover of PIns, we stimulated the
neurons with the muscarinic agonist carbachol. This
increased both the cytosolic level of 3H-inositol and 3H-
IPs, as well as the efﬂux by ~2-fold (Figs. 4b, d), the
proportion of inositol generated by carbachol-stimulated
hydrolysis of PIP2 that appeared in the efﬂux was 47 ± 4%.
This indicates that efﬂux is concentration dependent and,
surprisingly, that much of the inositol coming from PIP2
hydrolysis equilibrates rapidly with extracellular inositol.
We conﬁrmed that PIP2 hydrolysis was also stimulated by
membrane depolarization with 40mM KCl as previously
reported41 (see Supplemental Figure S3), and noticed that
the rate of inositol efﬂux increased with this stimulation
as it did with carbachol (data not shown).
Fig. 4 The ﬂux of inositol across the plasma membrane and the effect of drugs. a, c Neurons were treated with either 1 mM lithium or 3 μM
FLUO for 20 h before extraction, and also labelled with 3H-inositol for the last 1 h. Some neurons were also stimulated with carbachol (1 mM) during
the 1-h labelling period. The histograms show the cpm/well in extracts of the cytosol (light grey bars) and extracts of membranes from the same
neurons (dark grey bars). Data are means ± SEM, n= 4. Data in (a–b) and (c–d) are from two separate platings and each experiment was repeated
with similar results. For comparison of inﬂux and efﬂux, the white bar shows the efﬂux from control neurons as shown in (b) and (d) but plotted on
the same scale as the cytosol and lipid. b, d Neurons were labelled to steady-state for 5 days (D6–11) with 3H-inositol and treated with either 1 mM
lithium or 3 μM FLUO for the last 20 h before washing away the radioactivity, re-feeding the neurons with media and drugs, and returning the
neurons to the CO2 incubator for 1 h. Some neurons were also stimulated with carbachol (1 mM) during the 1-h incubation. The white bars show the
amount of inositol present in the collected media after 1 h. The light grey bars show the amount remaining in the cytosol (acid extraction) of the
same neurons. Data are means ± SEM, n= 4
Saiardi and Mudge Translational Psychiatry  (2018) 8:175 Page 7 of 12
Drugs have indirect effects on inositol uptake by neurons
We found no evidence to indicate that the inhibitory
effects of either lithium or FLUO on inositol uptake were
due to direct inhibition of transport. Lithium did not
change either the total cytosolic content of 3H-inositol
(Fig. 3a) or the efﬂux (Fig. 4b), although it greatly
decreased the incorporation of 3H-inositol into lipid PIns
(Fig. 4a); this indicates that lithium’s inhibition of inositol
inﬂux is indirect and is linked to the rate of PIns synthesis.
Carbachol stimulation decreased lipid PIns and increased
both cytosolic content and efﬂux of 3H-components
(Fig. 4b), indicating that much of the inositol recycled
from PIns hydrolysis equilibrates with the extracellular
space. The large increase in IP1 resulting from lithium
inhibition of PIns synthesis during carbachol stimulation
did not change inositol efﬂux relative to unstimulated
control efﬂux (Fig. 4b).
Treatment with FLUO, however, decreased both inﬂux
(Fig. 4c) and efﬂux of 3H-inositol in the same proportion
to the decrease in cytosolic 3H-inositol (Fig. 4d). Intri-
guingly, the increased efﬂux due to carbachol stimulation
of PIP2 hydrolysis was almost identical ( ±3 %) in FLUO-
treated neurons compared with controls (Fig. 4d). These
last results indicate that FLUO, as with lithium, does not
inhibit efﬂux directly.
The results with lithium and FLUO treatment conﬁrm
the effects of these drugs on inhibiting the rate of PIns
synthesis and inositol uptake, respectively, indicating that
this simpliﬁed inﬂux experiment may be useful in drug
screening compared with the CDP-DAG experiments
used in the past10,28.
Indeed, we used the inﬂux of 3H-inositol to assess the
dose responses to drugs when added for 20 h prior to the
transport studies. We found signiﬁcant effects at <1mM
for lithium and <1 μM for FLUO (Supplemental Figure
S5). Lithium also inhibits the enzyme GSK-3, so we tested
a small-molecule inhibitor of GSK-3 – SB415286 (a gift
from GlaxoSmithKline, Harlow, UK) – in this uptake
assay using a dose that inhibits 45% of neuronal GSK-3
activity42. SB415286 had no effect on either inositol
uptake or PIns synthesis (data not shown), indicating that
lithium inhibition of GSK-3 does not contribute to the
decrease in the rate of PIns synthesis.
FLUO stimulates incorporation of recycled inositol into
PIns
As 3H-inositol inﬂux and efﬂux were both decreased in
the presence of FLUO, whereas steady-state levels of PIns
were the same as controls, we investigated whether FLUO
stimulates incorporation of recycled inositol into PIns,
thereby decreasing the need for additional uptake of
inositol. We labelled neurons for 1 h and found that the
total inﬂux of 3H-inositol was decreased by 34% in FLUO-
treated neurons compared with controls (Fig. 5a); the
ratio of membrane to cytosolic radioactivity in FLUO-
treated neurons compared with controls was identical
(1.93 vs 1.96: Fig. 5b). We washed away the extracellular
3H-inositol from a second set of neurons from the same
plating and incubated them for a further hour. After the
second hour, the cytosolic content of 3H-inositol in con-
trol neurons was decreased as expected, but cytosolic
content and efﬂux of 3H-inositol in FLUO-treated neu-
rons was further decreased to ~43% that of controls (Fig.
5a). As predicted, there was a highly signiﬁcant (p < 0.005)
30% increase in the ratio of membrane to cytosolic
radioactivity in FLUO-treated neurons compared with
controls in the second hour (Fig. 5b). This result is con-
sistent with the notion that FLUO stimulates greater
incorporation of recycled inositol into PIns compared
with controls. The apparent inhibitory effect of FLUO on
synthesis of PIns as assessed by incorporation of 3H-
inositol into PIns is therefore due to the decrease in
inositol inﬂux and efﬂux. Instead, the shift to the use of
recycled inositol indicates a stimulatory effect of FLUO on
the rate of PIns synthesis.
Discussion
Much of the 28-year debate about lithium’s inhibition of
IMPase as a possible therapeutic target has focussed on
Fig. 5 FLUO effects on the incorporation of recycled inositol into
lipid PIns. a Histograms on the left show the total uptake (cytosol
plus membrane) of 3H-inositol in 1 h in control compared with 3 µM
FLUO-treated neurons as indicated. Histograms on the right show the
efﬂux from neurons in the second hour after washing away the
radioactivity. The symbols indicate highly signiﬁcant (p < 0.005)
decreases in FLUO-treated neurons compared with controls. Data are
means ± SEM, n= 4. b The ratio of radioactivity in the membranes to
that in the cytosol after 1 h compared with the ratio after 2 h. The
same neurons generated the left and right histogram pairs in both (a)
and (b). The increase in the ratio in the second hour for FLUO-treated
neurons compared with controls was highly signiﬁcant (p < 0.005) as
indicated ***
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lithium’s effects on regulation of inositol and PIns steady-
state levels in the brain or in neurons. As noted pre-
viously, it was the rate of synthesis and not the levels of
PIns in pancreatic slices that initially attracted the atten-
tion of Hokin and Hokin40 and led to the discovery of the
PIns cycle and its importance in intracellular signal-
ling43,44. Our ﬁnding that lithium causes a marked inhi-
bition of the rate of synthesis of PIns, and hence turnover
of PIP2, without affecting steady-state levels refutes one of
the main arguments against IMPase being a relevant
primary therapeutic target of lithium in the treatment of
BD. The difference between lithium effects on steady-
state levels and the synthesis rate in neurons suggests that
there may be more than one pool of PIP2 with different
rates of synthesis, which would not be surprising given the
elaborate structure of neurons illustrated in our electron
micrographs and the ubiquitous PIP2 and InsP signalling
network. In addition, if the rates of PIP2 hydrolysis and
synthesis are matched, as indicated by Batty and
Downes29, then the turnover rate in any compartment
could change without producing a change in steady-state
levels.
A large accumulation of IP1 is taken as an indication of
rapid turnover of PIns45, which we attribute to the elec-
trical activity in our cultured neurons, and which may
account for the difference between our results and those
of del Rio et al.10,41. It is striking that the average 8-fold
increase in levels of accumulated IP1 resulting from
lithium treatment is 1.6-fold higher than the levels of
intracellular inositol. We therefore suggest that the ther-
apeutically relevant consequence of lithium’s inhibition of
IMPase is not to limit the availability of recycled inositol
for PIns re-synthesis, as originally suggested46: rather, it is
the accumulation of IP1, which then inhibits PIns synth-
esis. The ability of inositol to reverse the effects of lithium
could then be explained by the need for additional inositol
to overcome the inhibition of PI-synthase by IP1. We have
preliminary evidence that IP1 does inhibit PI-synthase in
membrane extracts. This enzyme, however, is unusual in
that it also catalyses the reverse phosphoinositol:inositol
exchange reaction47,48 and so a full analysis of the inhi-
bition is outside the scope of the present article.
Although the levels of inositol in human ventricular
CSF are estimated to be in the range of 110–160 μM36,37,
it is not known what the levels are in the restricted
extracellular spaces surrounding different neurons and in
the different compartments of individual neurons. It is
likely that these inositol levels may become limiting,
particularly in regions of neurons that have rapid PIns
turnover – for example, synapses or growth cones. Thus,
lithium’s effect mediated by IP1 inhibition of PI-synthase
could be more pronounced in speciﬁc neuronal com-
partments, as well as in speciﬁc neurons, even if lithium
inhibits IMPase and causes IP1 accumulation in all
neurons. Indeed, inositol-reversible effects of lithium and
anticonvulsant mood stabilizers on neuronal function
have only been observed in specialized neuronal struc-
tures such as growth cones23 and synapses49.
Our study also shows that ~50% of the total intracellular
pool of inositol, including that generated by PIP2 hydro-
lysis, is exchanged with extracellular inositol each hour
and that rapid PIns synthesis preferentially uses newly
imported inositol. These results add further support to
the idea that the therapeutically relevant consequence of
lithium’s inhibition of IMPase is not to limit the avail-
ability of recycled inositol, which has been the subject of
much research. In addition, our study looked speciﬁcally
at rapid turnover of 3H-PIns as we measured labelling in
neurons after 1 h, whereas studies such as with brains of
IMPA-1 −/− mice looked at labelling of PIns after 24 h39,
which would include many cell types, as well as many
pools of neuronal PIns.
It is important to note that vesicle release is triggered by
extracellular Ca++ inﬂux via channels50 and that PIP2
signalling, rather than IP3 signalling, plays a crucial role in
regulating vesicle recycling processes involved in synaptic
plasticity51,52, as well as activity of many ion channels53.
Lithium seems to indirectly decrease inositol inﬂux into
the neurons, however, which may be due to a close link
between uptake of inositol and PIns turnover. The rapid
ﬂux of inositol we describe in our electrically active
neurons raises the possibility that inositol may be
acquired from the extracellular space via synaptic vesicle
recycling rather than by a transporter. PI-synthase is
located in the endoplasmic reticulum54 and PIns is then
inserted into the plasma membrane by a fusion process:
linking the supply of inositol to PIns turnover in synapses
via vesicle recycling is therefore an intriguing notion.
Note also that HMIT is located in an endosomal com-
partment25,28, where it may supply inositol for PI-
synthase.
In the context of new drug development, there has been
recent emphasis on lithium’s ability to inhibit GSK-3
rather than IMPase as the most relevant therapeutic pri-
mary drug target8,21,55, although no GSK-3 inhibitors have
progressed to clinical trials for BD. We previously showed
that the inositol-reversible effects of lithium on neurons
are not mimicked by GSK-3 inhibitors, although such
inhibitors do mimic other neuronal effects of 10 mM
lithium22. In the present study, we show that GSK-3
inhibition does not mimic lithium’s inhibition in PIns
synthesis, conﬁrming that these two targets of lithium are
not necessarily linked. Our present results with both
lithium and FLUO, together with our discovery that
neurons use extracellular inositol for rapid PIns turnover,
should re-establish PIns turnover as a primary drug target
for BD treatment. Atack et al.56 designed drugs based on
the structure of IP1 to inhibit IMPase, although these
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drugs failed to reach clinical trials due to delivery pro-
blems. Our suggestion that IP1 inhibits PI-synthase makes
this second enzyme a possibility for new drug screening
studies. A recent drug screen identiﬁed a new IMPase
inhibitor Ebselen57, but its ability to mimic lithium effects
on IP1 accumulation or PIns turnover has yet to be
established, surprisingly. The large accumulation of IP1 in
response to lithium results from the mechanism whereby
lithium only binds to IMPase when the substrate is bound,
resulting in the unusual uncompetitive inhibition. It
seems unlikely that a non-competitive inhibitor such as
Ebselen would mimic this crucial aspect of lithium’s
inhibition. Lithium has recently been shown to change the
excitability of neurons derived by stem cell technology
from lithium-responsive and non-responsive indivi-
duals58: It would be interesting to know whether this
effect can be reversed by inositol vs. GSK-3 inhibitors as
PIP2 is known to regulate voltage-sensitive channel
properties53.
To our knowledge, the ﬁnding that FLUO has a major
effect on inositol levels and PIns synthesis at doses of
< 1 µM has not been described previously. We initially
tested FLUO in our growth cone assay because of our
interest in FLUO’s destabilizing effects on mood in BD,
and the results suggested that FLUO might have effects on
the PIns cycle. In the present experiments, we ﬁrst used
FLUO as a tool to manipulate inositol levels in order to
explore inositol’s role in regulating PIns synthesis in
neurons, just as lithium was used to manipulate the levels
of IPs in early experiments on IP3 signalling
59. Our ﬁnd-
ing, however, that FLUO stimulates PIns turnover by
increasing the incorporation of inositol generated by PIP2
hydrolysis into PIns re-synthesis offers an explanation for
FLUO’s ability to cancel out the effects of lithium and
VPA on growth cones, where we suggest that inositol
uptake capacity may be limited. We found signiﬁcant drug
effects at < 1 mM for lithium and < 3 µM for FLUO
(Supplemental Figure S5). Both concentrations are ther-
apeutically relevant: lithium blood levels are 0.4–1.0 mEq/
l and human brain levels of FLUO reach 10–15 µM during
treatment for depression60. Note that FLUO is known to
accumulate inside cells61, and we assume that the effects
on inositol and PIns are due to intracellular FLUO (as are
the effects of lithium intracellular). The cortical neurons
we use do not produce serotonin, and so the FLUO effects
we describe are independent of serotonin re-uptake.
FLUO is marketed as the SSRI Prozac, but it has many
effects in the brain in addition to its effects on serotonin
re-uptake62,63 and it is possible that some of these are
secondary to effects on PIns synthesis and PIP2 turnover.
In the treatment of BD, lithium is primarily an anti-
manic drug although it also limits the frequency of mood
swings, whereas FLUO acts as an antidepressant. The
opposing effects of lithium and FLUO on the rate of PIns
turnover – lithium inhibits and FLUO stimulates – has
interesting implications for the nature of mood instability
in BD. One possibility is that there is faulty regulation in
bipolar individuals of PIP2 regulated vesicle recycling,
which in turn regulates the activity of neuronal circuits
involved in plasticity, including those involved in mood
control. Our results with lithium and FLUO provide a
neurochemical explanation of why these drugs can mod-
ulate mood swings in opposing ways. It is also possible
that FLUO’s effects on PIns turnover contribute to its
antidepressant action in unipolar depression but, more
importantly, to its destabilizing effects on mood in bipolar
individuals when prescribed without the balance of a
mood stabilizer such as lithium or VPA2,3.
Taken together, our results suggest a new hypothesis for
the consequences of lithium’s inhibition of IMPase in
brain neurons. Because of the uncompetitive nature of
this inhibition, IP1 accumulates in neuronal compart-
ments where PIns turnover is high and we suggest that the
accumulated IP1 competitively inhibits PI-synthase. The
inositol reversibility of lithium’s effects could then be
explained by an increase in inositol uptake leading to a
reversal of IP1 inhibition of PI-synthase, rather than to
alleviation of hypothetical ‘inositol depletion’. In addition,
lithium indirectly inhibits uptake of inositol that is used
for rapid PIns synthesis in the neurons. These two aspects
of lithium’s effects on neurons could conﬁne the inhibi-
tion of PIns synthesis to neurons that do not express the
high capacity SMITs, and to compartments, such as
synapses, where extracellular inositol may be limiting. We
propose that such susceptible synapses include those in
the neocortex involved in mood control.
In summary, our results show that PIns synthesis and
turnover of PIP2 in neurons is a target for lithium and
FLUO, which are the most frequently prescribed mood-
stabilizing and antidepressant drugs, respectively. The
ﬁnding that both drugs used at therapeutically relevant
doses have effects that converge on the regulation of the
rate of neuronal PIns synthesis suggests that PIns meta-
bolism, as well as the uptake of inositol as sites for psy-
chiatric drug action should be re-evaluated. Our results
also suggest a possible explanation for the destabilizing
effects of antidepressants in BD and point to dysregula-
tion of PIns turnover at synapses within some neuronal
circuits as a possible underlying cause of BD. In addition,
our results raise unexpected questions about how neurons
acquire inositol and open new avenues for investigation of
how neurons regulate PIP2 turnover.
Acknowledgements
The experiments in this study were carried out by the two senior authors: each
participated in all aspects of the project, although A.S. was mainly responsible
for the HPLC analyses and A.W.M. was mainly responsible for the neuron
experiments, and enzyme assays. The paper was written by both authors.
Electron microscopy was performed by Dr. Jemima Burden (LMCB). We thank
Saiardi and Mudge Translational Psychiatry  (2018) 8:175 Page 10 of 12
Samantha Campbell (UCL BSc student) for help with some early experiments.
We also thank Benjamin Mudge for help with graphics and acknowledge his
'FM Compressor analogy' of BD that motivated the drug experiments. This
work was supported by the Medical Research Council funding to the MRC-
LMCB University Unit at UCL, award code MC_U12266, and by the MRC
programme funding to A.S. (MC_UU_12018/4) and by the Stanley Medical
Research Institute.
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41398-018-0235-2).
Received: 26 July 2018 Accepted: 31 July 2018
References
1. Suppes, T. et al. The Stanley Foundation Bipolar Treatment Outcome Network.
II. Demographics and illness characteristics of the ﬁrst 261 patients. J. Affect.
Disord. 67, 45–59 (2001).
2. Goodwin, G. M. & Young, A. H. The British Association for Psychopharma-
cology guidelines for treatment of bipolar disorder: a summary. J. Psycho-
pharmacol. 17(4 Suppl), 3–6 (2003).
3. Ghaemi, S. N., Hsu, D. J., Soldani, F. & Goodwin, F. K. Antidepressants in bipolar
disorder: the case for caution. Bipolar Disord. 5, 421–433 (2003).
4. Hallcher, L. M. & Sherman, W. R. The effects of lithium ion and other agents on
the activity of myo-inositol-1-phosphatase from bovine brain. J. Biol. Chem.
255, 10896–10901 (1980).
5. Andreassi, C. et al. An NGF-responsive element targets myo-inositol mono-
phosphatase-1 mRNA to sympathetic neuron axons. Nat. Neurosci. 13,
291–301 (2010).
6. Klein, P. S. & Melton, D. A. A molecular mechanism for the effect of lithium on
development. Proc. Natl Acad. Sci. USA 93, 8455–8459 (1996).
7. Ohnishi, T. et al. Spatial expression patterns and biochemical properties dis-
tinguish a second myo-inositol monophosphatase IMPA2 from IMPA1. J. Biol.
Chem. 282, 637–646 (2007).
8. Phiel, C. J. & Klein, P. S. Molecular targets of lithium action. Annu. Rev. Phar-
macol. Toxicol. 41, 789–813 (2001).
9. Pittet, D., Schlegel, W., Lew, D. P., Monod, A. & Mayr, G. W. Mass changes in
inositol tetrakis- and pentakisphosphate isomers induced by chemotactic
peptide stimulation in HL-60 cells. J. Biol. Chem. 264, 18489–18493 (1989).
10. del Rio, E., Nicholls, D. G. & Downes, C. P. Characterization of the effects of
lithium and inositol on phosphoinositide turnover in cerebellar granule cells in
primary culture. J. Neurochem. 66, 517–524 (1996).
11. del Rio, E., Shinomura, T., van der Kaay, J., Nicholls, D. G. & Downes, C. P.
Disruption by lithium of phosphoinositide signalling in cerebellar granule cells
in primary culture. J. Neurochem. 70, 1662–1669 (1998).
12. Agranoff, B. W. & Fisher, S. K. Inositol, lithium, and the brain. Psychopharmacol.
Bull. 35, 5–18 (2001).
13. Sherman, W. R., Leavitt, A. L., Honchar, M. P., Hallcher, L. M. & Phillips, B. E.
Evidence that lithium alters phosphoinositide metabolism: chronic adminis-
tration elevates primarily D-myo-inositol-1-phosphate in cerebral cortex of the
rat. J. Neurochem. 36, 1947–1951 (1981).
14. Berry, G. T., Buccafusca, R., Greer, J. J. & Eccleston, E. Phosphoinositide deﬁ-
ciency due to inositol depletion is not a mechanism of lithium action in brain.
Mol. Genet. Metab. 82, 87–92 (2004).
15. Moore, G. J. et al. Temporal dissociation between lithium-induced changes in
frontal lobe myo-inositol and clinical response in manic-depressive illness. Am.
J. Psychiatry 156, 1902–1908 (1999).
16. Silverstone, P. H., McGrath, B. M. & Kim, H. Bipolar disorder and myo-inositol: a
review of the magnetic resonance spectroscopy ﬁndings. Bipolar Disord. 7,
1–10 (2005).
17. Agam, G. et al. Knockout mice in understanding the mechanism of action of
lithium. Biochem. Soc. Trans. 37(Pt 5), 1121–1125 (2009).
18. Bersudsky, Y., Shaldubina, A., Agam, G., Berry, G. T. & Belmaker, R. H. Homo-
zygote inositol transporter knockout mice show a lithium-like phenotype.
Bipolar Disord. 10, 453–459 (2008).
19. Cryns, K. et al. IMPA1 is essential for embryonic development and lithium-like
pilocarpine sensitivity. Neuropsychopharmacology 33, 674–684 (2008).
20. Li, X. & Jope, R. S. Is glycogen synthase kinase-3 a central modulator in mood
regulation? Neuropsychopharmacology 35, 2143–2154 (2010).
21. Tobe, B. T. D. et al. Probing the lithium-response pathway in hiPSCs implicates
the phosphoregulatory set-point for a cytoskeletal modulator in bipolar
pathogenesis. Proc. Natl Acad. Sci. USA 114, E4462–E4471 (2017).
22. Di Daniel, E., Cheng, L., Maycox, P. R. & Mudge, A. W. The common inositol-
reversible effect of mood stabilizers on neurons does not involve GSK3 inhi-
bition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-
inositol transporters. Mol. Cell. Neurosci. 32, 27–36 (2006).
23. Williams, R. S., Cheng, L., Mudge, A. W. & Harwood, A. J. A common
mechanism of action for three mood-stabilizing drugs. Nature 417, 292–295
(2002).
24. Wong, Y. H., Kalmbach, S. J., Hartman, B. K. & Sherman, W. R. Immunohisto-
chemical staining and enzyme activity measurements show myo-inositol-1-
phosphate synthase to be localized in the vasculature of brain. J. Neurochem.
48, 1434–1442 (1987).
25. Uldry, M. et al. Regulated exocytosis of an H+/myo-inositol symporter at
synapses and growth cones. EMBO J. 23, 531–540 (2004).
26. Guo, W. et al. Developmental regulation of Na+/myo-inositol cotransporter
gene expression. Brain. Res. Mol. Brain. Res. 51, 91–96 (1997).
27. Maallem, S., Berod, A., Mutin, M., Kwon, H. M. & Tappaz, M. L. Large dis-
crepancies in cellular distribution of the tonicity-induced expression of
osmoprotective genes and their regulatory transcription factor TonEBP in rat
brain. Neuroscience 142, 355–368 (2006).
28. Di Daniel, E. et al. Evaluation of expression and function of the H+/myo-
inositol transporter HMIT. BMC. Cell. Biol. 10, 54 (2009).
29. Batty, I. H. & Downes, C. P. The mechanism of muscarinic receptor-stimulated
phosphatidylinositol resynthesis in 1321N1 astrocytoma cells and its inhibition
by Li+. J. Neurochem. 65, 2279–2289 (1995).
30. Fisher, S. K., Novak, J. E. & Agranoff, B. W. Inositol and higher inositol phos-
phates in neural tissues: homeostasis, metabolism and functional signiﬁcance.
J. Neurochem. 82, 736–754 (2002).
31. Novak, J. E., Turner, R. S., Agranoff, B. W. & Fisher, S. K. Differentiated human
NT2-N neurons possess a high intracellular content of myo-inositol. J. Neu-
rochem. 72, 1431–1440 (1999).
32. Brewer, G. J., Torricelli, J. R., Evege, E. K. & Price, P. J. Optimized survival of
hippocampal neurons in B27-supplemented Neurobasal, a new serum-free
medium combination. J. Neurosci. Res. 35, 567–576 (1993).
33. Azevedo, C. & Saiardi, A. Extraction and analysis of soluble inositol polypho-
sphates from yeast. Nat. Protoc. 1, 2416–2422 (2006).
34. Dove, S. K. & Michell, R. H. Inositol lipid-dependent functions in Saccharomyces
cerevisiae: analysis of phosphatidylinositol phosphates. Methods Mol. Biol. 462,
59–74 (2009).
35. Coady, M. J., Wallendorff, B., Gagnon, D. G. & Lapointe, J. Y. Identiﬁcation of a
novel Na+/myo-inositol cotransporter. J. Biol. Chem. 277, 35219–35224 (2002).
36. Shetty, H. U., Holloway, H. W. & Schapiro, M. B. Cerebrospinal ﬂuid and plasma
distribution of myo-inositol and other polyols in Alzheimer disease. Clin. Chem.
42, 298–302 (1996).
37. Swahn, C. G. Gas chromatographic-mass spectrometric determination of myo-
inositol in human cerebrospinal ﬂuid. J. Neurochem. 45, 331–334 (1985).
38. York, J. D., Ponder, J. W. & Majerus, P. W. Deﬁnition of a metal-dependent/Li
(+)-inhibited phosphomonoesterase protein family based upon a conserved
three-dimensional core structure. Proc. Natl Acad. Sci. USA 92, 5149–5153
(1995).
39. Sade, Y. et al. IP3 accumulation and/or inositol depletion: two downstream
lithium’s effects that may mediate its behavioral and cellular changes. Transl.
Psychiatry 6, e968 (2016).
40. Hokin, M. R. & Hokin, L. E. Enzyme secretion and the incorporation of P32 into
phospholipides of pancreas slices. J. Biol. Chem. 203, 967–977 (1953).
41. del Rio, E., Nicholls, D. G. & Downes, C. P. Involvement of calcium inﬂux in
muscarinic cholinergic regulation of phospholipase C in cerebellar granule
cells. J. Neurochem. 63, 535–543 (1994).
Saiardi and Mudge Translational Psychiatry  (2018) 8:175 Page 11 of 12
42. Cross, D. A. et al. Selective small-molecule inhibitors of glycogen synthase
kinase-3 activity protect primary neurones from death. J. Neurochem. 77,
94–102 (2001).
43. Irvine, R. F. & Schell, M. J. Back in the water: the return of the inositol phos-
phates. Nat. Rev. Mol. Cell Biol. 2, 327–338 (2001).
44. Wilson, M. S., Livermore, T. M. & Saiardi, A. Inositol pyrophosphates: between
signalling and metabolism. Biochem. J. 452, 369–379 (2013).
45. Atack, J. R., Cook, S. M., Watt, A. P. & Ragan, C. I. Measurement of lithium-
induced changes in mouse inositol(1)phosphate levels in vivo. J. Neurochem.
59, 1946–1954 (1992).
46. Berridge, M. J., Downes, C. P. & Hanley, M. R. Neural and developmental actions
of lithium: a unifying hypothesis. Cell 59, 411–419 (1989).
47. Lykidis, A., Jackson, P. D., Rock, C. O. & Jackowski, S. The role of CDP-
diacylglycerol synthetase and phosphatidylinositol synthase activity levels in
the regulation of cellular phosphatidylinositol content. J. Biol. Chem. 272,
33402–33409 (1997).
48. McPhee, F., Lowe, G., Vaziri, C. & Downes, C. P. Phosphatidylinositol synthase
and phosphatidylinositol/inositol exchange reactions in turkey erythrocyte
membranes. Biochem. J. 275(Pt 1), 187–192 (1991).
49. Kim, H. J. & Thayer, S. A. Lithium increases synapse formation between hip-
pocampal neurons by depleting phosphoinositides. Mol. Pharmacol. 75,
1021–1030 (2009).
50. Sudhof, T. C. Neurotransmitter release: the last millisecond in the life of a
synaptic vesicle. Neuron 80, 675–690 (2013).
51. Di Paolo, G. & De Camilli, P. Phosphoinositides in cell regulation and mem-
brane dynamics. Nature 443, 651–657 (2006).
52. Di Paolo, G. et al. Impaired PtdIns(4,5)P2 synthesis in nerve terminals produces
defects in synaptic vesicle trafﬁcking. Nature 431, 415–422 (2004).
53. Suh, B. C. & Hille, B. Regulation of ion channels by phosphatidylinositol 4,5-
bisphosphate. Curr. Opin. Neurobiol. 15, 370–378 (2005).
54. Kim, Y. J., Guzman-Hernandez, M. L. & Balla, T. A highly dynamic ER-derived
phosphatidylinositol-synthesizing organelle supplies phosphoinositides to
cellular membranes. Dev. Cell. 21, 813–824 (2011).
55. Gould, T. D., Zarate, C. A. & Manji, H. K. Glycogen synthase kinase-3: a target for
novel bipolar disorder treatments. J. Clin. Psychiatry 65, 10–21 (2004).
56. Atack, J. R. Inositol monophosphatase inhibitors–lithium mimetics? Med. Res.
Rev. 17, 215–224 (1997).
57. Singh, N. et al. A safe lithium mimetic for bipolar disorder. Nat. Commun. 4,
1332 (2013).
58. Stern, S. et al. Neurons derived from patients with bipolar disorder divide into
intrinsically different sub-populations of neurons, predicting the patients’
responsiveness to lithium. Mol. Psychiatry 23, 1453–1465 (2018).
59. Berridge, M. J., Downes, C. P. & Hanley, M. R. Lithium ampliﬁes agonist-
dependent phosphatidylinositol responses in brain and salivary glands. Bio-
chem. J. 206, 587–595 (1982).
60. Karson, C. N. et al. Human brain ﬂuoxetine concentrations. J. Neuropsychiatry
Clin. Neurosci. 5, 322–329 (1993).
61. Mukherjee, J., Yang, Z. Y. & Lew, R. N-(6-18F-ﬂuorohexyl)-N-methylpropargy-
lamine: a ﬂuorine-18-labeled monoamine oxidase B inhibitor for potential use
in PET studies. Nucl. Med. Biol. 26, 111–116 (1999).
62. Bonanno, G. et al. Chronic antidepressants reduce depolarization-evoked
glutamate release and protein interactions favoring formation of SNARE
complex in hippocampus. J. Neurosci. 25, 3270–3279 (2005).
63. Maya Vetencourt, J. F. et al. The antidepressant ﬂuoxetine restores plasticity in
the adult visual cortex. Science 320, 385–388 (2008).
Saiardi and Mudge Translational Psychiatry  (2018) 8:175 Page 12 of 12
